S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Denmark says Nord Stream 1 pipelines stop leaking
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Denmark says Nord Stream 1 pipelines stop leaking
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Denmark says Nord Stream 1 pipelines stop leaking
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
S&P 500   3,585.62
DOW   28,725.51
QQQ   267.26
Why This Bear Market Is Not Even Close to Being Done…
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Denmark says Nord Stream 1 pipelines stop leaking
Denmark says Nord Stream 1 natural gas pipeline has also stopped leaking
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Brazil holds historic election with Lula against Bolsonaro
US shift away from coal hits tribal community in New Mexico
In 20 years, this little-known trader didn’t have a single losing year… (Ad)
Tesla sales bounce back in Q3 but fall short of estimates
Allies aim for risky Russian oil price cap as winter nears
NASDAQ:IFRX

InflaRx - IFRX Stock Forecast, Price & News

$2.64
+0.04 (+1.54%)
(As of 09/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$2.51
$2.70
50-Day Range
$1.39
$3.14
52-Week Range
$0.78
$5.69
Volume
101,256 shs
Average Volume
132,765 shs
Market Capitalization
$116.69 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00

InflaRx MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
165.2% Upside
$7.00 Price Target
Short Interest
Healthy
1.12% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.04mentions of InflaRx in the last 14 days
Based on 11 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.06) to ($1.09) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.11 out of 5 stars

Medical Sector

588th out of 1,095 stocks

Pharmaceutical Preparations Industry

279th out of 547 stocks

IFRX stock logo

About InflaRx (NASDAQ:IFRX) Stock

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company also develops INF904, an oral, small molecule drug candidate for the undisclosed chronic inflammatory and autoimmune diseases; and IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Receive IFRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InflaRx and its competitors with MarketBeat's FREE daily newsletter.

IFRX Stock News Headlines

An All-In-One Guide for Trading Metals
So many want to add metals to their portfolio. Metals can be a great way to protect your money and hedge against market downturns. But first, you need to know how. Download our FREE Guide to Metals Futures today from RJO Futures to get the information that you need to know to trade futures in metals. pixel
An All-In-One Guide for Trading Metals
So many want to add metals to their portfolio. Metals can be a great way to protect your money and hedge against market downturns. But first, you need to know how. Download our FREE Guide to Metals Futures today from RJO Futures to get the information that you need to know to trade futures in metals. pixel
Here's Why InflaRx (NASDAQ:IFRX) Must Use Its Cash Wisely
What 5 Analyst Ratings Have To Say About InflaRx
InflaRx: Q2 Earnings Insights - Benzinga
InflaRx GAAP EPS of €0.01 - Seeking Alpha
See More Headlines
Receive IFRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for InflaRx and its competitors with MarketBeat's FREE daily newsletter.

IFRX Company Calendar

Last Earnings
8/05/2022
Today
10/02/2022
Next Earnings (Estimated)
11/04/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IFRX
Fax
N/A
Employees
55
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.00
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+165.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-53,990,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$2.82 per share

Miscellaneous

Free Float
N/A
Market Cap
$116.69 million
Optionable
Not Optionable
Beta
1.33

Key Executives

  • Dr. Niels C. Riedemann M.D. (Age 50)
    Ph.D., Co-Founder, CEO & Exec. Director
  • Prof. Renfeng Guo M.D. (Age 52)
    Co-Founder, Chief Scientific Officer & Exec. Director
  • Dr. Thomas Taapken Ph.D. (Age 57)
    Chief Financial Officer
  • Ms. Nicole Bertsch
    Sr. Director & Head of HR
  • Dr. Maria Habel PH.D. (Age 40)
    Head of Preclinical R&D
  • Ms. Evelyn Roth-Geissler Ph.D.
    VP & Head of Clinical Operations
  • Dr. Bruce P. Burnett Ph.D.
    VP & Head of Medical Affairs
  • Mr. Christian Schmid
    VP and Head of Legal Affairs & Corp. Counsel
  • Mr. Kafi Boaten
    Sr. Director and Head of Supply & Clinical Trial Supplies
  • Mr. Peter Hurt Ph.D.
    Sr. Director and Head of Drug Safety & Pharmacovigiliance













IFRX Stock - Frequently Asked Questions

Should I buy or sell InflaRx stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for InflaRx in the last year. There are currently 1 hold rating, 2 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" IFRX shares.
View IFRX analyst ratings
or view top-rated stocks.

What is InflaRx's stock price forecast for 2022?

4 Wall Street analysts have issued 1 year price objectives for InflaRx's shares. Their IFRX share price forecasts range from $6.00 to $8.00. On average, they predict the company's stock price to reach $7.00 in the next year. This suggests a possible upside of 165.2% from the stock's current price.
View analysts price targets for IFRX
or view top-rated stocks among Wall Street analysts.

How have IFRX shares performed in 2022?

InflaRx's stock was trading at $4.76 at the start of the year. Since then, IFRX stock has decreased by 44.5% and is now trading at $2.64.
View the best growth stocks for 2022 here
.

When is InflaRx's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, November 4th 2022.
View our IFRX earnings forecast
.

How were InflaRx's earnings last quarter?

InflaRx (NASDAQ:IFRX) posted its earnings results on Friday, August, 5th. The company reported $0.01 earnings per share for the quarter, beating analysts' consensus estimates of ($0.34) by $0.35.

What other stocks do shareholders of InflaRx own?

Based on aggregate information from My MarketBeat watchlists, some companies that other InflaRx investors own include Dynavax Technologies (DVAX), Gilead Sciences (GILD), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), AbbVie (ABBV), OPKO Health (OPK), Capricor Therapeutics (CAPR), Citius Pharmaceuticals (CTXR), Kadmon (KDMN) and Moderna (MRNA).

When did InflaRx IPO?

(IFRX) raised $100 million in an initial public offering on Wednesday, November 8th 2017. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO.

What is InflaRx's stock symbol?

InflaRx trades on the NASDAQ under the ticker symbol "IFRX."

How do I buy shares of InflaRx?

Shares of IFRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is InflaRx's stock price today?

One share of IFRX stock can currently be purchased for approximately $2.64.

How much money does InflaRx make?

InflaRx (NASDAQ:IFRX) has a market capitalization of $116.69 million. The company earns $-53,990,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis.

How can I contact InflaRx?

InflaRx's mailing address is WINZERLAER STR. 2, JENA 2M, 07745. The official website for the company is www.inflarx.de. The company can be reached via phone at 493641508180 or via email at jordan.zwick@inflarx.de.

This page (NASDAQ:IFRX) was last updated on 10/2/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.